Results 191 to 200 of about 34,135 (204)

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

Lancet, The, 2010
Michael Friedlander, Clare L Scott, Ana Oaknin   +2 more
exaly  

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial

Lancet Oncology, The, 2020
Joaquin Mateo, Nuria Porta, Christy Ralph   +2 more
exaly  

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

New England Journal of Medicine, 2012
Jonathan A Ledermann, Charlie Gourley, Michael Friedlander   +2 more
exaly  

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

New England Journal of Medicine, 2018
Kathleen N Moore, Nicoletta Colombo, Giovanni Scambia   +2 more
exaly  

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

Lancet, The, 2010
Andrew N J Tutt, Mark E Robson, Susan M Domchek   +2 more
exaly  

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

New England Journal of Medicine, 2015
Joaquin Mateo, Suzanne Carreira, Shahneen Sandhu   +2 more
exaly  

Olaparib improves PFS

Nature Reviews Clinical Oncology, 2017
Diana Romero
exaly  

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

Lancet Oncology, The, 2014
Jonathan A Ledermann, Philipp Harter, Charlie Gourley   +2 more
exaly  

Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial

Lancet Oncology, The, 2018
Boris Y Alekseev, Jacek Jassem, Fred Saad   +2 more
exaly  

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Lancet Oncology, The, 2017
Eric Pujade-Lauraine, Jonathan A Ledermann, Val Gebski   +2 more
exaly